Clinical outcomes and left ventricular recovery in patients with solid malignancies developing Takotsubo syndrome: a retrospective cohort study
https://orcid.org/0000-0002-9593-1013
Aida Malik Al Kindy
Waleed Dawelbeit
Marwa Makhlouf
Ahmed Mustafa Basuoni
https://orcid.org/0000-0002-2473-6544
Abstract
Takotsubo cardiomyopathy (TTS) is an acute heart failure syndrome characterized by transient left ventricle (LV) systolic dysfunction, often triggered by physical or emotional stress. Although several registries, observational studies, and meta-analyses have demonstrated an association between malignancy and adverse outcomes in Takotsubo syndrome, data describing the interplay between cancer stage, treatment exposure, ventricular recovery, and mortality in patients with solid malignancies remain limited. Material and methods: We retrospectively analyzed adult patients with solid malignancies treated at a Comprehensive Cancer Center between November 2021 and December 2025 who developed Takotsubo syndrome. TTS was diagnosed according to the InterTAK Diagnostic Score together with characteristic echocardiographic findings and, when indicated, additional anatomical or tissue characterization. Demographic characteristics, cancer type and stage, clinical presentation, electrocardiogram and biomarkers findings, imaging results, and outcomes were collected. Primary outcome was all-cause mortality. Secondary outcomes included cause-specific mortality, recovery of left ventricular systolic function, and resumption of cancer therapy. Results: A total of 26 consecutive patients developed TTS during the study period. Median age 64.5 years (IQR 52.2 - 69.5); 61.5% were female. Advanced or metastatic cancer was present in 42.3% of patients. Sepsis occurred in 50.0%, and major cancer-related surgery in 30.8%. The median InterTAK Diagnostic Score was 75.5 (IQR 64.5–80.0); 73.1% of patients had scores ≥70. Overall mortality was 38.5% (10/26), and all deaths were attributed to cancer-related causes; no cardiac-related deaths occurred. Advanced/metastatic disease was associated with higher mortality (80.0% vs. 18.8%, p = 0.015), and all deaths occurred in patients receiving non-curative treatment. In exploratory multivariable analysis, advanced/metastatic cancer was associated with increased odds of death (adjusted OR 11.49, p = 0.021). Follow-up echocardiography was available in 18 patients; all demonstrated normalization of left ventricular systolic function (LVEF ≥50%), with a median time to documented recovery of 10 days (IQR 6–21). Conclusions: Takotsubo cardiomyopathy syndrome in patients with solid malignancies was associated with high cancer-related mortality, whereas left ventricular dysfunction was largely reversible among survivors. Outcomes appeared to be more associated with oncologic disease burden than with cardiac dysfunction.
##plugins.themes.bootstrap3.article.details##
Takotsubo syndrome, Stress cardiomyopathy, Solid malignancy, Prognosis, Cancer-associated Takotsubo syndrome, Cardio-oncology
2. Ghadri JR, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Eur Heart J. 2018 Jun 7;39(22):2047-2062. doi: 10.1093/eurheartj/ehy077. PMID: 29850820; PMCID: PMC5991205.
3. Nguyen TH, Stansborough J, Ong GJ, et al. Antecedent cancer in Takotsubo syndrome predicts both cardiovascular and long-term mortality. Cardiooncology. 2019 Nov 22;5:20. doi: 10.1186/s40959-019-0053-6. PMID: 32154026; PMCID: PMC7048128.
4. Ghadri JR, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018 Jun 7;39(22):2032-2046. doi: 10.1093/eurheartj/ehy076. PMID: 29850871; PMCID: PMC5991216.
5. Osawa T, Tajiri K, Ieda M, Ishizu T. Clinical outcomes of takotsubo syndrome in patients with cancer: a systematic review and meta-analysis. Front Cardiovasc Med. 2023 Sep 29;10:1244808. doi: 10.3389/fcvm.2023.1244808. PMID: 37840966; PMCID: PMC10570743.
6. Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients. Cardiooncology. 2019 Jul 1;5:7. doi: 10.1186/s40959-019-0042-9. PMID: 32154014; PMCID: PMC7048040.
7. Macedo AVS, Almeida GLG de, Rehder MHH dos S. Takotsubo Cardiomyopathy in Patients with Cancer. ABC Heart Fail Cardiomyopathy. 2022;2(4):374–80. doi:10.36660/abchf.20220083
8. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. Erratum in: Eur Heart J. 2023 May 7;44(18):1621. doi: 10.1093/eurheartj/ehad196. PMID: 36017568.
9. Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022 Jan 31;43(4):280-299. doi: 10.1093/eurheartj/ehab674. PMID: 34904661; PMCID: PMC8803367.
10. Ghadri JR, Cammann VL, Jurisic S, et al. A novel clinical score (InterTAK Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry. Eur J Heart Fail. 2017 Aug;19(8):1036-1042. doi: 10.1002/ejhf.683. Epub 2016 Dec 7. PMID: 27928880.
11. Samul-Jastrzębska J, Roik M, Wretowski D, et al. Evaluation of the InterTAK Diagnostic Score in differentiating Takotsubo syndrome from acute coronary syndrome. A single center experience. Cardiol J. 2021;28(3):416-422. doi: 10.5603/CJ.a2019.0086. Epub 2019 Sep 6. PMID: 31489610; PMCID: PMC8169192.
12. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017 Mar;67(2):93-99. doi: 10.3322/caac.21388. Epub 2017 Jan 17. PMID: 28094848.
13. Madias JE. What is/are the trigger(s) of Takotsubo syndrome in cancer patients receiving chemotherapy? Int J Cardiol. 2016 Nov 1;222:253. doi: 10.1016/j.ijcard.2016.07.246. Epub 2016 Jul 30. PMID: 27497104.
14. Tini G, Arcari L, Mistrulli R, et al. A contemporary update on cancer and Takotsubo syndrome. Front Cardiovasc Med. 2024 Jan 8;10:1301383. doi: 10.3389/fcvm.2023.1301383. PMID: 38259302; PMCID: PMC10800806.
15. Brunetti ND, Tarantino N, Guastafierro F, et al. Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy. Heart Fail Rev. 2019 Jul;24(4):481-488. doi: 10.1007/s10741-019-09773-6. PMID: 30806878.
16. Arcari L, Cacciotti L, Limite LR, et al. Clinical characteristics of patients with takotsubo syndrome recurrence: An observational study with long-term follow-up. Int J Cardiol. 2021 Apr 15;329:23-27. doi: 10.1016/j.ijcard.2020.12.047. Epub 2020 Dec 24. PMID: 33359286.
17. Giza DE, Lopez-Mattei J, Vejpongsa P, et al. Stress-Induced Cardiomyopathy in Cancer Patients. Am J Cardiol. 2017 Dec 15;120(12):2284-2288. doi: 10.1016/j.amjcard.2017.09.009. Epub 2017 Sep 19. PMID: 29096885.
18. Jamil G, Al Shamisi A, AlShamsi F, Agha A. Validation of the InterTAK Diagnostic Score for Differentiating Takotsubo Syndrome from Acute Coronary Syndrome in a Middle Eastern Population. J Clin Med. 2025 Nov 3;14(21):7806. doi: 10.3390/jcm14217806. PMID: 41227202; PMCID: PMC12608723.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.